Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nektar's NKTR-214 IO Deal With Bristol Looks Even Sweeter With More Data

Executive Summary

Stock soars yet again with a positive data update for immuno-oncology star NKTR-214, a better-than-expected fourth quarter and catalysts for other pipeline candidates coming soon.

Advertisement

Related Content

Keeping Track: Shionogi, Fresenius Kabi Join July Approval Parade; Busy August Expected
A Plea For Patience: Bristol/Nektar's Opdivo/NKTR-214 Combo Responses Deepen Over Time
Immuno-Oncology: What To Watch At ASCO 2018
Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space
Scrip's Rough Guide To IL-2: Mother Of All Cytokines
Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape
Bristol Goes In Big On New Valentine Nektar
Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well
Lilly, Nektar Partner On 'Stimulating' IL-2 Drug In Autoimmune Diseases
Nektar Turns Up The Heat On Partnering Talks For NKTR-181

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100498

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel